Illumina (NASDAQ:ILMN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Illumina (NASDAQ:ILMN) in a research note published on Tuesday morning. The brokerage issued a buy rating on the life sciences company’s stock.

Several other brokerages also recently commented on ILMN. Evercore ISI dropped their target price on shares of Illumina from $195.00 to $175.00 and set an outperform rating on the stock in a report on Tuesday, June 11th. TD Cowen lifted their target price on Illumina from $122.00 to $126.00 and gave the stock a hold rating in a report on Wednesday, August 7th. Scotiabank dropped their price target on Illumina from $185.00 to $176.00 and set a sector outperform rating for the company in a research note on Monday, May 6th. Robert W. Baird lifted their target price on Illumina from $119.00 to $124.00 and gave the company a neutral rating in a research report on Wednesday, August 7th. Finally, Citigroup boosted their price target on Illumina from $140.00 to $155.00 and gave the stock a buy rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of Moderate Buy and an average price target of $151.10.

Illumina Trading Down 0.4 %

Illumina stock traded down $0.49 during trading hours on Tuesday, reaching $128.31. 384,772 shares of the company’s stock traded hands, compared to its average volume of 2,115,762. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.75. Illumina has a fifty-two week low of $89.00 and a fifty-two week high of $172.69. The firm has a market capitalization of $20.44 billion, a price-to-earnings ratio of -15.80 and a beta of 1.15. The firm’s 50 day moving average is $114.35 and its 200-day moving average is $122.67.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.24. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. Illumina’s revenue for the quarter was down 5.4% on a year-over-year basis. During the same period last year, the company posted $0.32 EPS. On average, analysts predict that Illumina will post 1.5 earnings per share for the current year.

Hedge Funds Weigh In On Illumina

Several institutional investors have recently added to or reduced their stakes in ILMN. Bouvel Investment Partners LLC grew its holdings in Illumina by 1.3% during the first quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock worth $899,000 after buying an additional 84 shares in the last quarter. UMB Bank n.a. grew its stake in shares of Illumina by 7.0% during the 2nd quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock worth $140,000 after acquiring an additional 88 shares during the period. STF Management LP lifted its holdings in Illumina by 3.5% during the 4th quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock worth $368,000 after purchasing an additional 90 shares in the last quarter. Global Retirement Partners LLC lifted its holdings in Illumina by 12.3% during the 1st quarter. Global Retirement Partners LLC now owns 856 shares of the life sciences company’s stock worth $118,000 after purchasing an additional 94 shares in the last quarter. Finally, Gulf International Bank UK Ltd raised its holdings in shares of Illumina by 0.7% in the 1st quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock valued at $1,862,000 after acquiring an additional 98 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.